The BRCA gene test is most often a blood test. A doctor, nurse or medical technician inserts a needle into a vein, usually in your arm, to draw the blood sample needed for testing. Your blood sample then goes to a lab for DNA analysis.
In some cases, other sample types are collected for DNA analysis, including saliva or skin biopsy samples. If you have a family history of cancer and are interested in pursuing a saliva DNA test, discuss it with your doctor. He or she can refer you to a genetic counselor who can determine the most appropriate sample type for genetic testing.
It takes several weeks before test results are available. You meet with your genetic counselor to learn your test results, discuss their implications and go over your options. Federal and state laws help ensure the privacy of your genetic information and protect against discrimination in health insurance and employment.
May 01, 2015
- BRCA1 and BRCA2: Cancer risk and genetic testing. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed June 3, 2013.
- Isaacs C, et al. Genetic testing for hereditary breast and ovarian cancer syndrome. http://www.uptodate.com/home. Accessed June 3, 2013.
- Lindor NM, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Human Mutation. 2012;33:8.
- Kurion AW, et al. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: Findings from the breast cancer family registry. Journal of Clinical Oncology. 2011;29:4505.
- Pruthi S, et al. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clinic Proceedings. 2010;85:1111.
- Mackay J, et al. Genetic counseling for hereditary predisposition to ovarian and breast cancer. Annals of Oncology. 2010;21:vii 334.
- Raby BA, et al. Genetic counseling and testing. http://www.uptodate.com/home. Accessed June 3, 2013.
- Isaacs C, et al. Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations. http://www.uptodate.com/home. Accessed June 3, 2013.
- Kurian AW,et al. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers, Journal of Clinical Oncology. 2010;28:222.
- Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. April 24, 2015.